Sarepta Therapeutics Inc. (NASDAQ:SRPT) VP Jayant Aphale sold 35,000 shares of the company’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the sale, the vice president now owns 21,490 shares of the company’s stock, valued at $1,074,500. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Sarepta Therapeutics Inc. (NASDAQ:SRPT) opened at 60.97 on Friday. The company’s market cap is $2.92 billion. Sarepta Therapeutics Inc. has a 52 week low of $8.00 and a 52 week high of $61.60. The stock has a 50 day moving average of $30.01 and a 200 day moving average of $21.91.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the firm posted ($0.87) earnings per share. Equities research analysts predict that Sarepta Therapeutics Inc. will post ($4.17) EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of SRPT. State Street Corp raised its position in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares during the period. Franklin Resources Inc. bought a new position in Sarepta Therapeutics during the first quarter valued at about $13,506,000. A.R.T. Advisors LLC bought a new position in Sarepta Therapeutics during the first quarter valued at about $7,461,000. Eagle Asset Management Inc. bought a new position in Sarepta Therapeutics during the second quarter valued at about $6,756,000. Finally, Emerald Mutual Fund Advisers Trust bought a new position in Sarepta Therapeutics during the second quarter valued at about $4,712,000. Institutional investors own 72.09% of the company’s stock.

Several brokerages have commented on SRPT. Cowen and Company restated a “market perform” rating on shares of Sarepta Therapeutics in a report on Monday, August 15th. Janney Montgomery Scott upgraded shares of Sarepta Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $30.00 to $65.00 in a report on Monday. Jefferies Group restated an “underperform” rating and issued a $7.00 price objective on shares of Sarepta Therapeutics in a report on Saturday, June 25th. Robert W. Baird restated an “outperform” rating and issued a $23.00 price objective on shares of Sarepta Therapeutics in a report on Monday, July 18th. Finally, JMP Securities restated an “underperform” rating and issued a $10.00 price objective on shares of Sarepta Therapeutics in a report on Sunday, July 24th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $48.70.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.